Brought to you by 
Series B raises $32.4mm for Catabasis
15 Nov 2013
Executive Summary
Catabasis Pharmaceuticals Inc. (developing therapies for inflammatory, immunological, and metabolic diseases) brought in $32.4mm via a Series B financing to first-time backer Lightstone Ventures, which was joined by an undisclosed public crossover fund and all existing shareholders Advanced Technology Ventures, Clarus Ventures, MedImmune Ventures, and SV Life Sciences. Catabasis says the money should last into 2015 and help the company prep for Phase III trials of its triglyceride-lowering candidate CAT2003 and support ongoing development of other candidates based on its SMART linker conjugate technology.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series B raises $32.4mm for Catabasis
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice